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Genetic and biochemical analyses show that IL-23p19 plays a
central role inmediating bacteria-induced colitis in interleukin-
10-deficient (IL-10/) mice. The molecular mechanisms
responsible for the dysregulated innate host response leading to
enhanced IL-23 gene expression in IL-10/ mice are poorly
understood. In this study, we investigated the role of Bcl3 in
controlling LPS-induced IL-23p19 gene expression in bone
marrow-derived dendritic cells (BMDC) isolated from IL-10/
mice.We report higher IL-23p19mRNAaccumulation and pro-
tein secretion in LPS-stimulated BMDC isolated from IL-10/
compared with WT mice. Lipopolysaccharide (LPS)-induced B
cell leukemia 3 (Bcl3) expression was strongly impaired (90%
decrease) in IL-10/ BMDC comparedwithWTBMDC. Chro-
matin immunoprecipitation demonstrated enhanced RelA
binding to the IL-23p19 promoter in IL-10/ compared with
WT BMDC. Bcl3 overexpression decreased LPS-induced
IL-23p19 gene expression in IL-10/ BMDC, which correlated
with enhanced NF-B p50 binding and decreased RelA binding
to the gene promoter. Conversely, Bcl3 knockdown enhanced
LPS-induced IL-23p19 gene expression in WT BMDC. More-
over, LPS-induced IL-23p19 gene expression was significantly
enhanced inBcl3/BMDCcomparedwithWTBMDC. In con-
clusion, enhanced LPS-induced IL-23p19 gene expression in
IL-10/ mice is due to impaired Bcl3 expression leading to
diminishedp50 and enhancedRelA recruitment to the IL-23p19
promoter.
Inflammatory bowel diseases (IBDs)2 exemplified by Crohn
disease and ulcerative colitis are chronic intestinal inflamma-
tory disorders causing abdominal pain, diarrhea, and bleeding.
Although the etiology of IBD still eludes the medical research
field, experimental models of colitis have provided important
clues about the pathogenesis of the disease. From this large
body of work, it has become clear that a dysregulated host
immune response to the endogenous intestinal microflora is a
prerequisite to the development of the disease (1–4). The fail-
ure to implement a functional network of immunosuppressive
cytokines dampening host responses to the abundant micro-
biota in conjunction with an overly active production of proin-
flammatory mediators likely contribute to the development of
IBD (1, 5). The importance of a proper immunosuppressive
response tomicroorganisms is clearly illustrated in interleukin-
10-deficient (IL-10/) mice. These mice become intolerant to
their intestinal microflora and spontaneously develop colitis
through aberrant activation of effector T cells (6–8). Among
the various inflammatory mediators released by the mucosal
immune cells, IL-23p19was identified as the key factor promot-
ing T cell-mediated chronic intestinal inflammation (9).
Indeed, IL-23p19 and IL-10 double knock-out mice fail to
develop spontaneous colitis, whereas IL-12p35 and IL-10 dou-
ble knock-out mice are as susceptible to colitis as IL-10/
mice. Therefore, IL-23 but not IL-12 is the key mediator of the
disease (9, 10). This new paradigm established IL-23 as an
inducer ofmemory T lymphocytes producing IL-17 (Th17) and
IL-6, both cytokines critical in mediating chronic inflamma-
tion. Interestingly, CD40- and Helicobacter hepaticus-induced
colitis in Rag-1/ mice is mediated by intestinal dendritic/
myeloid cells producing IL-23, suggesting that this cytokine
also plays a role in innate immune pathology (11, 12). More-
over, monoclonal anti-IL-23p19 neutralizing antibody pre-
vented and treated established experimental colitis (13).
Finally, genome-wide scan analysis indicates that genetic vari-
ants of IL-23R associate either positively or negatively with the
development of the disease (14). Altogether, these findings
established IL-23 as a keymediator of chronic intestinal inflam-
mation and as a potential therapeutic target.
IL-10 is a potent multifunctional immunoregulatory cyto-
kine that regulates the expression of numerous proinflamma-
tory cytokines, chemokines, and costimulatory molecules
expressed by various immune and non-immune cells (15). The
molecularmechanism responsible for IL-10 inhibitory action is
diverse and includes activation of the heme oxygenase/carbon
monoxide pathway (16), inhibition of the NF-B pathway (17–
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19),mitogen-activated protein kinase activity (20), STAT3 acti-
vation (21–23), and induction of SOCS-3 and B cell leukemia 3
(Bcl3) (24–26). Although the exact mechanism of IL-10-medi-
ated immunosuppressive effects is still unclear, evidence points
to a mechanism involving changes in the rate of transcriptional
activity (27).
IL-23p19 is the critical mediator of experimental colitis in
IL-10/ mice, but the molecular mechanisms involved in the
dysregulated production of this mediator remain unknown. In
this study, we demonstrate that the increased IL-23p19 gene
expression in IL-10/ mice is due to a defective induction of
Bcl3, thereby impairing recruitment of the transcriptionally
inactive NF-B p50 subunit while facilitating binding of the
transcriptionally active RelA subunit to the gene promoter.
These data indicate that Bcl3 plays a critical role in the resolu-
tion of LPS-induced IL-23p19 gene expression and may repre-
sent a potential target for the treatment of IBDs.
EXPERIMENTAL PROCEDURES
RNA Extraction and RT-PCR Analysis—RNA was isolated
using TRIzol (Invitrogen), reverse transcribed (1 g RNA), and
amplified using specific primers for mouse IL-23p19, Bcl3, and
GAPDH: IL-23p19 forward, 5-GCCCCGTATCCAGTGTGA-





The PCR products (8 l) were subjected to electrophoresis on
2% agarose gels containing GelStar fluorescent dye (Cambrex
BioScience Rockland, Rockland, ME). Fluorescence staining
was captured using anAlpha Imager 2000 (Alpha Innotech, San
Leandro,CA). Toprecisely quantify the expression of IL-23p19,
Bcl3, and GAPDH, real time PCR was conducted using an
Applied Biosystems 7700 sequence detection system. For PCR
2-l cDNA preparation, 150 nM final concentration of forward
and reverse primers and 6 l of QuantiTect SYBR Green PCR
Master Mix (Qiagen) in a total of 12 l were applied. The fol-
lowing PCR program was performed: 15 min at 95 °C (initial
denaturation); 20 °C/s temperature transition rate up to 95 °C
for 30 s, 45 s at 56 °C, 45 s at 72 °C, acquisition mode single,
repeated 40 times (amplification). Specificity and linearity (effi-
cacy) of amplification for each primer set (amplicon) was deter-
mined by melting curve analysis and calculation of the slope
from serial diluted samples as suggested by the manufacturer
(ABI, User Bulletin 2). Relative changes were determined using
the CT calculation method. The values were normalized to
the internal control GAPDH.
Western Blots—The cells were harvested and lysed in 1
Laemmli buffer, and the protein concentration was measured
using Bio-Rad quantification assay (Bio-Rad). Twenty micro-
grams of the protein extracts were subjected to electrophoresis
on 10% SDS-polyacrylamide gels and transferred to Hybond-C
Extra nitrocellulose membranes (Amersham Biosciences).
Anti-Bcl3 (c-14; Santa Cruz Biotechnology) and GAPDH anti-
bodies were used to detect Bcl3 and GAPDH, respectively. All
of the antibodies were used at a 1:1,000 dilution in a solution
containing 5% milk in TBS-T. Immunoreactive proteins were
detected using an ECL detecting kit (Amersham Biosciences).
Cytokine Measurement—The cells were stimulated for 24 h
with LPS (5 g/ml), the supernatants were collected, and the
cytokine levels were measured using commercially available
kits specific for IL-23p19 (eBioscience, San Diego, CA) and
IL-12p70 (PharMingen/BDBioscience, SanDiego, CA) accord-
ing to themanufacturers’ instructions. The cytokine levels were
determined in triplicate culture supernatants in each separate
experiment.
Cell Culture and Treatment of Bone Marrow-derived Den-
dritic Cells—Wild type (WT) IL-10/ mice (129SvEv back-
ground) andWTBcl3/ mice (C57B6 background) between 6
and 10 weeks of age were used to generate bone marrow cells
from femora and tibiae. Red blood cells were lysed using red
blood cell lysis buffer (Sigma), and the cells were cultured in
24-well low adherence plates (Costar, Corning, NY) in com-
pletemedium containing RPMI 1640 plus 10% heat-inactivated
fetal calf serum (HyClone, Logan, UT), 2mM L-glutamine, 1mM
sodiumpyruvate, 5 105 M 2-mercaptoethanol, and 50g/ml
gentamycin in the presence of recombinant murine granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) and
IL-4 (both 10 ng/ml; Peprotech, Rocky Hill, NJ). The floating
cells were gently removed, the medium was refreshed at day 3,
and the cells were collected at day 6. The cells were washed
twice and incubated overnight in complete medium without
IL-4/GM-CSF. Flow cytometry analysis demonstrated a
homogenous cell population with greater than 85% CD11c
cells and less than 2% T cells (data not shown). For cell stimu-
lation, 2.5  106 cells (cytokine measurement) or 3  106 cells
(proteins, RNA)were plated in 6- or 24-well plates, respectively.
The cells were stimulated with LPS (5 g/ml, from Escherichia
coli 0111:B4; Sigma) in the presence or absence of recombinant
murine IL-10 (12 h of preincubation, 10 ng/ml; Peprotech). For
NF-B inhibitory experiments, BMDC were pretreated with
the IB phosphorylation inhibitor BAY 11-7082 (25 M) (Cal-
biochem, San Diego, CA) for 1 h followed by stimulation with
LPS (5 g/ml) at various time points.
Plasmids and siRNATransfections—Transfection of BMDCs
was performed using the Nucleofector (Amaxa Inc., Gaithers-
burg, MD) according to the manufacturer’s instructions. The
constitutive active cytomegalovirus Bcl3 plasmid (a generous
gift of A. S. Baldwin, University of North Carolina at Chapel
Hill), an empty control vector pcDNA,Bcl3 siRNA (knockdown
experiments; sc-29790; Santa Cruz Biotechnology) and scram-
bled siRNA (negative control; sc-37007; Santa Cruz Biotech-
nology) were used for transfection of murine BMDC. Transfec-
tion efficacy of BMDC as measured using pmaxGFP (5
g/transfection) was estimated at 50%. The BMDCwere col-
lected on day 5 and washed twice in phosphate-buffered saline.
Subsequently, 3  106 cells were resuspended in 100 l of
human DC nucleofection solution (Amaxa), and the samples
were transferred into certified cuvettes (Amaxa) and transfected
by using the program X-001. The same programs were used for
transfectionwith plasmids and siRNA. Following transfection, the
BMDCwere cultured in completemediumcontainingRPMI1640
plus 1%heat-inactivated fetal calf serum (HyClone), 2mM L-gluta-
mine, 1mMsodiumpyruvate, 5 105M2-mercaptoethanol, and
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50g/ml gentamycinwithout IL-4 orGM-CSF, and the cellswere
stimulated accordingly.
Chromatin Immunoprecipitation (ChIP) Analysis—Murine
BMDCs were stimulated with LPS (5 g/ml) at various time
points, and ChIP assay was performed using a ChIP assay kit
(Upstate-Cell Signaling Solutions, Temecula, CA) according to
the manufacturer’s specifications as described previously (23).
Immunoprecipitation was carried out overnight with 2 g of
p65 (c-20; Santa Cruz Biotechnology) or RNA polymerase II
(c-21; SantaCruzBiotechnology), p50 (sc-114; SantaCruz), and
Bcl3 (c-14; Santa Cruz) antibodies. PCR was performed with
total input DNA (5 l) and immunoprecipitated DNA (5 l)
using IL-23p19 promoter-specific primers: IL-23p19 proximal
promoter forward, 5-CAGGCAGATTACACAGGAAGG-3;
IL-23p19 proximal promoter reverse, 5-GCCCGCCCTTCA-
CACTA-3; IL-23p19 distal promoter forward, 5-GGGTCAT-
CATCGCTGTACTTT-3; and IL-23p19 distal promoter
reverse, 5-CGGCCCTGGTTTTGAAG-3. PCR was carried
out in a volume of 50 l containing final concentrations of 1
Taq buffer (Applied Biosystems, Foster City, CA), 50 nM prim-
ers, 0.5mM dNTPs, and 1 unit ofThermo aquaticus polymerase
(Applied Biosystems) using a 9700 Gene-Amp PCR system
cycler (Applied Biosystems). The PCR temperatures used were
95 °C for 15 s, 56 °C for 45 s, and 72 °C for 45 s followed by an
extension of 5 min at 72 °C. The PCR products were subjected
to electrophoresis on 2% agarose gels containing GelStar fluo-
rescent dye (Cambrex BioScience Rockland). Fluorescence
staining was captured using an Alpha Imager 2000 (Alpha
Innotech).
Statistical Analysis—Statistical significance was evaluated by
the two-tailed Student’s t test for unpaired data. Ap value of less
than 0.05 was considered statistically significant.
RESULTS
Experimentalmodels of colitis as well as human genetic anal-
ysis have linked IL-23p19 to the development of IBD. Because
IL-10/ mice develop colitis when housed under specific
pathogen-free conditions, we first investigated the expression
of IL-23p19 in IL-10/ versusWTmice. Germ-free IL-10/
and WT mice were transferred to specific pathogen-free con-
ditions, and 8weeks later,mesenteric lymphnodes (MLN)were
isolated, and IL-23p19 expression was analyzed by RT-PCR.
Increased IL-23p19 mRNA expression was observed in MLN
isolated from IL-10/ mice compared with WT mice, sug-
gesting a dysregulated pattern of expression in IL-10/ mice
(Fig. 1). Because IL-23p19 is mostly produced by antigen-pre-
senting cells (28, 29), we sought to understand the mechanism
of dysregulated IL-23p19 expression using BMDC cells gener-
ated from IL-10/ and WT mice. Interestingly, LPS-induced
IL-23p19 mRNA accumulation was prolonged in IL-10/
BMDC compared with WT mice (Fig. 2A). Dysregulated
IL-23p19 mRNA accumulation in IL-10/ BMDC was fol-
lowed by enhanced protein secretion (10-fold) (Fig. 2B). Of
note, preincubation with recombinant IL-10 (10 ng/ml) com-
pletely abrogated LPS-induced IL-23p19 secretion in IL-10/
BMDC.
IL-10/;MyD88/ mice failed to develop spontaneous
colitis and displayed marked reduction of LPS-induced NF-B
signaling (30, 31). We therefore investigated whether dysregu-
lated TLR/NF-B signaling was responsible for enhanced
IL-23p19 gene expression in IL-10/ mice. LPS-induced
IL-23p19 mRNA accumulation was markedly reduced in
IL-10/;MyD88/ BMDC compared with IL-10/ cells
FIGURE 1. IL-23p19 mRNA expression is elevated in MLN derived from
IL-10/ compared with WT mice. RT-PCR amplification of IL-23p19 from
MLN of WT or IL-10/ mice after being housed for 8 weeks under specific
pathogen-free conditions. MLN were lysed in TRIzol, total RNA was extracted
and reverse transcribed, and IL-23p19 mRNA expression was detected using
real time PCR (Applied Biosystems 7700 sequence detection system). The
results were normalized to the housekeeping gene GAPDH to ascertain sim-
ilar loading. The results are the means  S.D. of quadruplicate samples and
are from one of three independent experiments (*, p 	 0.05).
FIGURE 2. Dysregulated LPS-induced IL-23p19 gene expression in
IL-10/ compared with WT mice. A, prolonged LPS-induced IL-23p19
mRNA expression in IL-10/ compared with WT mice. Conventional reverse
transcriptase-PCR results from WT or IL-10/ BMDC after treatment with LPS
(5 g/ml) are shown for the indicated times. PCR products were separated on
a 2% agarose gel and stained with GelStar. The results are representative of
three independent experiments. B, IL-10 inhibits IL-23p19 protein secretion in
BMDC derived from IL-10/ mice. WT and IL-10/ BMDC were prestimu-
lated with IL-10 (10 ng/ml) overnight or left untreated. The cells were then
stimulated with LPS (5 g/ml) for 20 h, and the supernatants were collected.
IL-23p19 protein secretion was detected using enzyme-linked immunosor-
bent assay (*, p 	 0.05). The results show the means  S.D. from triplicate
cultures and are representative of three independent experiments.
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(data not shown). Because TLR signals are mediated largely
through the NF-B family of transcription factors, we next
investigated the role of NF-B in LPS-induced IL-23p19 gene
expression. Chromatin immunoprecipitation analysis
showed that LPS induced RelA recruitment to the NF-B
sites located at position 96 and 632 of the IL-23p19 gene
promoter (Fig. 3A). RNA polymerase II was recruited to the
proximal NF-B (96) binding site following LPS stimula-
tion. To determine the functional impact of LPS-induced
NF-B recruitment, BMDC were preincubated with the
pharmacological inhibitor Bay 11–7085 and then stimulated
with LPS. As shown in Fig. 3B, LPS-induced IL-23p19mRNA
accumulation was prevented in Bay 11–7085-treated WT
BMDC cells, which was preceded by blockade of IB deg-
radation (data not shown). Altogether, these findings dem-
onstrate that TLR/NF-B signaling is critical for LPS-in-
duced IL-23p19 gene expression.
We next sought to determine themechanism responsible for
dysregulated LPS-induced IL-23p19 gene expression in
IL-10/ mice. NF-B DNA binding activity was compared
between LPS-stimulated WT and IL-10/ BMDC using an
enzyme-linked immunosorbent assay-based assay. We
observed a 50% increase in RelA binding activity at 30 and 60
min in LPS-stimulated IL-10/ BMDC compared with WT
cells (data not shown). To gain more insight into the relation-
ship between NF-B DNA binding activity and endogenous
IL-23p19 gene expression, we compared RelA recruitment to
the IL-23p19 gene promoter betweenWTand IL-10/BMDC
using ChIP assay. Increased RelA recruitment to the IL-23p19
FIGURE 3. LPS-induced IL-23p19 mRNA expression is TLR/NF-B depend-
ent. A, LPS-induced RelA and RNA polymerase II recruitment to the IL-23p19
NF-B-binding sites. Bioinformatic analysis using transcription element
search software revealed two potential NF-B-binding sites in the murine
IL-23p19 promoter region at position 96 and 632 relative to the transcrip-
tion start site. WT BMDC were stimulated with LPS (5 g/ml) at the indicated
time points, and ChIP assays were performed using anti-RelA or anti-RNA
polymerase II antibodies as described under “Experimental Procedures.” The
results are representative of three independent experiments. PCR primers to
the 632 (left panel) or the 96 (right panel) were used. B, LPS-induced
IL-23p19 mRNA expression is NF-B-dependent. BMDC from WT mice were
preincubated (1 h) with the NF-B inhibitor Bay 11-7082 and then stimulated
in the absence or presence of LPS (5 g/ml) for 2 h. Total RNA was extracted
and analyzed for the levels of IL-23p19 and GAPDH mRNA using real time PCR
(*, p 	 0.05). The results are the means  S.D. of triplicate samples from one of
three independent experiments. Ab, antibody.
FIGURE 4. IL-10/ mice exhibit prolonged LPS-induced RelA (p65) bind-
ing to the IL-23p19 promoter after LPS stimulation. A, prolonged LPS-
induced RelA (p65) binding in IL-10/ compared with WT BMDC. The cells
were isolated from WT and IL-10/ mice and stimulated with LPS (5 g/ml)
for the indicated times. ChIP assays were performed using anti-RelA antibod-
ies as described under “Experimental Procedures.” PCR products were sepa-
rated on a 2% agarose gel and stained with GelStar. The results are represent-
ative of three independent experiments. B, Semi-quantitative analysis of RelA
binding to the IL-23p19 promoter (632). WT (white bars) and IL-10/ (black
bars) BMDC were stimulated with LPS (5 g/ml) at different time points, and
ChIP assays were performed as described above. Relative fold changes were
determined by semi-quantitative assay using the ABI 7700 sequence detec-
tion system as described under “Experimental Procedures.” The results are






































FIGURE 5. LPS-induced Bcl3 expression is impaired in IL-10/ compared
with WT mice. A, impaired LPS-induced Bcl3 expression in IL-10/ mice.
BMDC were isolated from WT or IL-10/ mice and stimulated with LPS (5
g/ml) for the indicated times. Total RNA was then extracted, and Bcl-3 mRNA
levels were analyzed using real time PCR. The data were normalized using the
housekeeping gene GAPDH. The results are the means  S.D. of triplicate
samples from one of three independent experiments. B, Bcl3 expression in
IL-10/ mice can be restored by stimulation with IL-10. BMDC were isolated
from IL-10/ mice and stimulated with IL-10 (10 ng/ml) for 24 h. Total pro-
tein was extracted, and 20 g was subjected to SDS-PAGE followed by immu-
noblotting with Bcl3 and GAPDH specific antibodies. The results are repre-
sentative of three independent experiments.
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promoter was observed in LPS-stimulated IL-10/ BMDC
comparedwithWTcells (Fig. 4A). Semi-quantitative analysis of
the ChIP assay using an ABI Prism 7700 sequence detection
system showed an increase of up to 6-fold in LPS-stimulated
IL-10/ BMDC compared with WT cells (Fig. 4B). Because
the kinetic and extent of IB degradation and NF-B nuclear
translocation is similar betweenWT and IL-10/ BMDC (23)
and because DNA binding activity is minimally impaired, we
investigated whether an IL-10-inducible nuclear factor was
responsible for controlling RelA recruitment to IL-23p19 gene
promoter.We focused our attention onB cell leukemia 3 (Bcl3),
an IL-10-inducible gene interacting with the p50 NF-B sub-
unit (26, 32–35).
As shown in Fig. 5A, Bcl3mRNA accumulation progressively
increased following LPS stimulation in WT BMDC, whereas
levels remained relatively low in IL-10/BMDC.The addition
of exogenous IL-10 strongly increased Bcl3 protein accumula-
tion in IL-10/ BMDC (Fig. 5B). These findings indicate that
decreased Bcl3 expression in IL-10/ BMDC correlates with
increased LPS-induced IL-23p19 expression. To test the func-
tional impact of Bcl3 on IL-23p19 expression, IL-10/ BMDC
were transfected with a Bcl3 expression vector and then stim-
ulated with LPS for various time points. Using an enhanced
green fluorescent protein plasmid control, transfection effi-
ciency was found to be up to 50% in BMDC with no significant
cell death (data not shown). Interestingly, LPS-induced
IL-23p19mRNAaccumulationwas strongly reduced (90%) in
Bcl3-transfected IL-10/ BMDC (Fig. 6). Western blot analy-
sis confirmed Bcl3 expression in transfected IL-10/ BMDC
(Fig. 6). To validate these findings, we knocked down Bcl3
FIGURE 6. IL-10/-derived BMDC overexpressing Bcl3 displayed abro-
gated IL-23p19 mRNA expression. Bcl3 overexpression abrogated LPS-in-
duced IL-23p19 mRNA expression in IL-10/ mice. BMDC were isolated from
IL-10/ mice and transfected with a constitutively expressing Bcl3 plasmid
or empty vector control (Cont.). BMDC were stimulated with LPS (5 g/ml) for
the indicated times. Total RNA was extracted and analyzed for levels of
IL-23p19 and GAPDH mRNA using real time PCR. Statistical analysis was per-
formed comparing 2-, 4-, 6-, and 8-h values between vector only and Bcl3-
transfected mice (*, p 	 0.05). The inset shows Bcl3 protein expression by
immunoblot in Bcl3-transfected IL-10/ derived BMDC. The results are rep-
resentative of three independent experiments.
FIGURE 7. Bcl3 knockdown leads to enhanced LPS-induced IL-23p19
expression in WT BMDC. BMDC were isolated from WT mice and transfected
with Bcl3 siRNA or scrambled siRNA (control, Cont.) using the Amaxa nucleo-
fector system. The cells were then stimulated with LPS (5 g/ml) for 4 h, total
RNA was extracted, and IL-23p19 mRNA expression was detected using real
time PCR. The data were normalized using the housekeeping gene GAPDH.
Statistical analysis was performed comparing LPS-stimulated BMDC (*, p 	
0.05). The inset shows decreased Bcl3 protein expression in Bcl3 siRNA-trans-
fected WT-derived BMDC. The results are the means  S.D. of triplicate sam-


































































































FIGURE 8. Enhanced LPS-induced IL-23p19 expression in Bcl3/ BMDC.
A, IL-23p19 mRNA expression in BMDC derived from WT and Bcl3/ mice.
BMDC were isolated from WT and Bcl3/ mice and stimulated with LPS (5
g/ml) for the indicated times. Total RNA was extracted and analyzed by
RT-PCR for Bcl3 mRNA expression. The data were normalized using the house-
keeping gene GAPDH. The results are means  S.D. of triplicate samples from
one of three independent experiments. B, IL-23p19 and C, IL-12p70 protein
secretions in BMDC derived from WT, Bcl3/ and IL-10/ mice. BMDC were
generated from WT (white bars), Bcl3/ (gray bars), and IL-10/ (black bars)
mice and stimulated LPS (50 ng/ml or 5 g/ml) for 20 h, and the supernatants
were collected. IL-23p19 and IL-12p70 protein secretion was detected using
enzyme-linked immunosorbent assay. (*, p 	 0.05). The results are the
means  S.D. of triplicate samples from one of three independent
experiments.
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expression inWT BMDC using siRNA. LPS-induced IL-23p19
mRNAaccumulationwas significantly increased inWTBMDC
transfectedwith Bcl3 siRNA (Fig. 7).Western blot analysis con-
firmed that Bcl3 siRNA effectively decreased Bcl3 expression.
Control siRNA had minimal effect in BMDC (Fig. 7). To
directly link Bcl3 to the regulation of IL-23p19 gene expression,
we generated BMDC from Bcl3/ mice. Fig. 8A shows
increased LPS-induced IL-23p19mRNA expression in Bcl3/
compared with WT BMDC. Concomitant to mRNA levels,
IL-23p19 secretion was higher in LPS-stimulated Bcl3/
BMDC compared with WT cells (Fig. 8B; 9-fold versus 3-fold;
p 	 0.05) although to a lesser extent than stimulated IL-10/
BMDC (14-fold versus 9-fold; p	 0.05). In contrast secretion of
IL-12p70, a Bcl3-independent gene (34), is similar between
Bcl3/ BMDC andWT cells, regardless of LPS concentration
(Fig. 8C). These findings identify Bcl3 as an important regulator
of IL-23p19 gene expression.
Bcl3 has been shown to enhance p50 inhibitory activity and
consequently down-modulate NF-B transcriptional activity
(26, 32–35). To gainmore insight into the relationship between
Bcl3, p50, and IL-23p19 gene expression, we performed ChIP
assays in Bcl3-transfected IL-10/ BMDC. As seen in Fig. 9,
p50 recruitment to the IL-23p19 gene promoter was progres-
sively decreased over time in LPS-stimulated IL-10/ BMDC,
whereas p50 levels remained elevated in Bcl3-transfected cells.
Decreased p50 binding in IL-10/ BMDC correlated with
enhanced RelA binding to the gene promoter and concomitant
increased in IL-23p19 mRNA accumulation (Fig. 9). Of note,
increased p50 binding in Bcl3-transfected IL-10/ BMDC
leads to a decreased p65 and sustained Bcl3 binding to the
IL-23p19 gene promoter.
In summary our data suggest that decreased Bcl3 expres-
sion in IL-10/ BMDC impairs p50 recruitment/binding to
the IL-23p19 gene promoter and favors RelA loading, lead-
ing to an increased gene expression.
DISCUSSION
In this study, we investigated the molecular mechanism
responsible for the control of IL-23p19 gene expression. We
report dysregulated levels of IL-23p19 secretion in BMDC
derived from IL-10/ compared withWTmice following LPS
stimulation. Similarly, IL-23p19 mRNA expression is strongly
enhanced in mesenteric lymph nodes isolated from colitic
IL-10/mice comparedwith healthyWTmice. This indicates
that in the absence of endogenous IL-10, innate response to
luminal bacterial products is dysregulated and leads to higher
IL-23p19 gene expression. Importantly, administration of neu-
tralizing IL-23p19 antibody prevents the early onset of colitis in
a colitic transfer model (13). In addition, an increased TLR-
dependent IL-23p19 mRNA expression was observed in IL-
10/-derived macrophages (36, 37). Consequently, our find-
ing that LPS induced higher IL-23p19 gene expression in
BMDC isolated from IL-10/mice correlateswith the key role
of this cytokine in this model of spontaneous colitis.
In an effort to understand the mechanism responsible for
dysregulated IL-23p19 gene expression in IL-10/ BMDC, we
investigated the impact of LPS-induced NF-B signaling in
BMDC. Using the NF-B pharmacological inhibitor Bay
11-7082, we demonstrated that LPS utilizes the NF-B signal-
ing cascade to induce IL-23p19 gene expression in BMDC. In
addition, we report that LPS enhanced RelA recruitment to two
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FIGURE 9. Bcl3 overexpression reduced LPS-induced RelA binding and enhanced p50 recruitment to the IL-23p19 promoter. BMDC were isolated from
IL-10/ mice and transfected with a constitutively expressing Bcl3 plasmid or an empty vector control (Cont.) for 16 h. BMDC were then stimulated with LPS
(5 g/ml) for the indicated times, and ChIP assays were performed using anti-p50, anti-p65, and anti-Bcl3 antibodies as described under “Experimental
Procedures.” PCR was performed using primers specific for the NF-B consensus site within the IL-23p19 gene promoter (632). PCR products were loaded on
a 2% agarose-gel and visualized with GelStar. The results are shown from one of three representative experiments.
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IL-23p19 gene promoter. This is in line with a recent report
showing that the IL-23p19 promoter region contains two
NF-B-binding sites essential for LPS-induced transcriptional
activity (38). Interestingly, enhanced RelA recruitment to the
IL-23p19 promoter was observed in IL-10/ BMDC mice
compared with WT mice. This enhanced RelA recruitment
correlated with prolonged LPS-induced IL-23p19 mRNA
expression and elevated IL-23p19 secretion. LPS-induced
IL-23p19 secretion is abrogated when IL-10/ BMDC receive
exogenous IL-10, suggesting that this immunosuppressivemol-
ecule triggers the expression of a factor controlling IL-23p19
gene expression. Because LPS-inducedBcl3mRNAand protein
expression was impaired in IL-10/ BMDC compared with
WT cells, we focused our attention on this IB-like protein.
This protein interacts exclusively with the NF-B transcrip-
tionally inactive p50 and p52 subunits (39–41). Here, we dem-
onstrated a functional relationship between Bcl3 expression
levels and LPS-induced IL-23p19 gene expression using various
molecular strategies. First, LPS-induced IL-23p19 gene expres-
sion is strongly inhibited in Bcl3-transfected IL-10/ BMDC.
This inhibitory effect was associated with enhanced Bcl3/p50
binding to the IL-23p19 gene promoter and concomitant
decreased p65 binding. This is in line with a recent observation
showing that Bcl3 overexpression enhanced p50 homodimer
binding to NF-B-binding sites in the tumor necrosis factor
promoter (32).
Second, knock-down experiments using Bcl3 RNA inter-
ference showed enhanced LPS-induced IL23p19 gene
expression in WT BMDC. Finally, Bcl3/ BMDC displayed
enhanced LPS-induced IL23p19 gene expression compared
with WT cells, although to a lesser extent than in IL-10/
cells. This suggests that Bcl3-independent factors are also
involved in the regulation of LPS-induced IL-23p19 gene
expression. Bcl3-deficient mice exhibit various immunolog-
ical defects including decreased T cell-dependent immuno-
globulin class switching, defective generation of influenza-
specific antibodies, and increased susceptibility to a variety
of other pathogenic infections, including Toxoplasma gon-
dii, Listeria monocytogenes, and Streptococcus pneumonia
(34, 42, 43). Interestingly, as opposed to IL-10/ mice,
Bcl3/ mice fail to spontaneously develop colitis, suggest-
ing a broader immunoregulatory impact of IL-10 on intesti-
nal homeostasis. Although LPS-induced IL-23p19 gene
expression is higher in Bcl3/ mice BMDC compared with
WT cells, the former also secrete higher amounts of IL-10
(data not shown). Therefore, higher IL-10 secretion in Bcl3
mice may dampen any spontaneous intestinal phenotype in
these mice. It would be of high interest to investigate the
impact of Bcl3 on chemically (dextran sodium sulfate or
2,4,6-trinitrobenzenesulfonic acid) induced experimental
colitis. A recent report by Zhang et al. (44) demonstrated
that p52/;Bcl3/ mice developed a profound breakdown
in central tolerance that resulted in fatal multiorgan inflam-
mation, whereas the loss of only p52 or Bcl3 had only minor
effects. Although the impact of p52 and Bcl3 on intestinal
homeostasis was not investigated, their data implicate Bcl3
and NF-B in the control of immunological self-tolerance,
which also plays a major role in IBD.
In summary, our study identifies the IL-10-inducible mole-
cule Bcl3 as a key regulator of LPS-induced IL-23p19 produc-
tion in BMDC. Bcl3 appears to control IL-23p19 gene expres-
sion through the regulation of p50 binding to the gene
promoter. Understanding the regulation of IL-23p19, a major
cytokine involved in chronic inflammatory diseases, will be key
to the development of future clinical treatments for diseases
like inflammatory bowel diseases.
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